hiv 1

Summary

Summary: The type species of LENTIVIRUS and the etiologic agent of AIDS (ACQUIRED IMMUNODEFICIENCY SYNDROME). It is characterized by its cytopathic effect and affinity for the T4-lymphocyte.

Top Publications

  1. ncbi Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand
    Supachai Rerks-Ngarm
    Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand
    N Engl J Med 361:2209-20. 2009
  2. ncbi Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection
    Brandon F Keele
    Departments of Medicine and Microbiology, University of Alabama at Birmingham, Birmingham, AL 35223, USA
    Proc Natl Acad Sci U S A 105:7552-7. 2008
  3. ncbi Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication
    Renate König
    Infectious and Inflammatory Disease Center, Burnham Institute for Medical Research, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
    Cell 135:49-60. 2008
  4. ncbi Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection
    Jesus F Salazar-Gonzalez
    University of Alabama at Birmingham, Birmingham, AL 35294, USA
    J Exp Med 206:1273-89. 2009
  5. ncbi Tetherin inhibits HIV-1 release by directly tethering virions to cells
    David Perez-Caballero
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY 10016, USA
    Cell 139:499-511. 2009
  6. ncbi Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism
    Janet L Douglas
    Oregon Health and Science University, Vaccine and Gene Therapy Institute, Beaverton, 97006, USA
    J Virol 83:7931-47. 2009
  7. ncbi Microbial translocation is a cause of systemic immune activation in chronic HIV infection
    Jason M Brenchley
    Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Med 12:1365-71. 2006
  8. ncbi Antibody neutralization and escape by HIV-1
    Xiping Wei
    Howard Hughes Medical Institute, University of Alabama at Birmingham, 720 South 20th Street, Kaul 816, Birmingham, Alabama 35294 0024, USA
    Nature 422:307-12. 2003
  9. ncbi Identification of host proteins required for HIV infection through a functional genomic screen
    Abraham L Brass
    Department of Genetics, Center for Genetics and Genomics, Brigham and Women s Hospital, Howard Hughes Medical Institute, Harvard Medical School, Boston, MA 02115, USA
    Science 319:921-6. 2008
  10. ncbi Early antiretroviral therapy and mortality among HIV-infected infants
    Avy Violari
    Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa
    N Engl J Med 359:2233-44. 2008

Research Grants

  1. Tat Transactivation
    BORIS MATIJA PETERLIN; Fiscal Year: 2010
  2. Tat Transactivation
    B Matija Peterlin; Fiscal Year: 2007
  3. Establishment fo HIV infection in cotton rats
    Jorge Blanco; Fiscal Year: 2007
  4. TRANSCRIPTION ACTIVATION BY HIV, TAT, HTLV TAX & HBV PX
    Michael Green; Fiscal Year: 2004
  5. Structure and Function of Ribonucleoprotein Complexes Modulating HIV Replication
    Tariq M Rana; Fiscal Year: 2010
  6. Cytidine deaminase and HIV-1 replication
    Hui Zhang; Fiscal Year: 2007
  7. Targeting Viral Envelope Glycoproteins with Synthetic Antibodies
    Jonathan Lai; Fiscal Year: 2010
  8. Methamphetamine, HIV, Neuroinflammation and Behavior
    Rodney Johnson; Fiscal Year: 2007
  9. The Enzymology of M-MuLV and HIV Replication
    JAMES CHAMPOUX; Fiscal Year: 2007
  10. The Enzymology of M-MuLV and HIV Replication
    JAMES CHAMPOUX; Fiscal Year: 2009

Detail Information

Publications251 found, 100 shown here

  1. ncbi Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand
    Supachai Rerks-Ngarm
    Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand
    N Engl J Med 361:2209-20. 2009
    ..The development of a safe and effective vaccine against the human immunodeficiency virus type 1 (HIV-1) is critical to pandemic control...
  2. ncbi Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection
    Brandon F Keele
    Departments of Medicine and Microbiology, University of Alabama at Birmingham, Birmingham, AL 35223, USA
    Proc Natl Acad Sci U S A 105:7552-7. 2008
    ....
  3. ncbi Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication
    Renate König
    Infectious and Inflammatory Disease Center, Burnham Institute for Medical Research, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
    Cell 135:49-60. 2008
    ..Taken together, the multiscale approach described here has uncovered multiprotein virus-host interactions that likely act in concert to facilitate the early steps of HIV-1 infection...
  4. ncbi Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection
    Jesus F Salazar-Gonzalez
    University of Alabama at Birmingham, Birmingham, AL 35294, USA
    J Exp Med 206:1273-89. 2009
    ..These findings reveal viral properties associated with mucosal HIV-1 transmission and a limited set of rapidly evolving adaptive mutations driven primarily, but not exclusively, by early cytotoxic T cell responses...
  5. ncbi Tetherin inhibits HIV-1 release by directly tethering virions to cells
    David Perez-Caballero
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY 10016, USA
    Cell 139:499-511. 2009
    ....
  6. ncbi Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism
    Janet L Douglas
    Oregon Health and Science University, Vaccine and Gene Therapy Institute, Beaverton, 97006, USA
    J Virol 83:7931-47. 2009
    ..Understanding the molecular mechanisms of both Vpu-dependent and -independent mediated antagonism of BST-2 will be critical for therapeutic strategies that exploit this novel viral function...
  7. ncbi Microbial translocation is a cause of systemic immune activation in chronic HIV infection
    Jason M Brenchley
    Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Med 12:1365-71. 2006
    ..These data establish a mechanism for chronic immune activation in the context of a compromised gastrointestinal mucosal surface and provide new directions for therapeutic interventions that modify the consequences of acute HIV infection...
  8. ncbi Antibody neutralization and escape by HIV-1
    Xiping Wei
    Howard Hughes Medical Institute, University of Alabama at Birmingham, 720 South 20th Street, Kaul 816, Birmingham, Alabama 35294 0024, USA
    Nature 422:307-12. 2003
    ..The evolving glycan shield thus represents a new mechanism contributing to HIV-1 persistence in the face of an evolving antibody repertoire...
  9. ncbi Identification of host proteins required for HIV infection through a functional genomic screen
    Abraham L Brass
    Department of Genetics, Center for Genetics and Genomics, Brigham and Women s Hospital, Howard Hughes Medical Institute, Harvard Medical School, Boston, MA 02115, USA
    Science 319:921-6. 2008
    ..This effort illustrates the power with which RNA interference and forward genetics can be used to expose the dependencies of human pathogens such as HIV, and in so doing identify potential targets for therapy...
  10. ncbi Early antiretroviral therapy and mortality among HIV-infected infants
    Avy Violari
    Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa
    N Engl J Med 359:2233-44. 2008
    ..We investigated antiretroviral-treatment strategies in the Children with HIV Early Antiretroviral Therapy (CHER) trial...
  11. ncbi HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor
    Christine Goffinet
    Department of Virology, University of Heidelberg, Heidelberg, Germany
    Cell Host Microbe 5:285-97. 2009
    ..Thus, HIV-1 Vpu suppresses the expression of the CD317 antiviral factor in human cells, and the species-specific resistance to this suppression may guide the development of small animal models of HIV infection...
  12. ncbi The immune response during acute HIV-1 infection: clues for vaccine development
    Andrew J McMichael
    Medical Research Council Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
    Nat Rev Immunol 10:11-23. 2010
    ..In this Review, we discuss recent studies on the kinetics and quality of early immune responses to HIV-1 and their implications for developing a successful preventive HIV-1 vaccine...
  13. ncbi Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection
    Eberhard W Fiebig
    Department of Laboratory Medicine, University of California, San Francisco, CA, USA
    AIDS 17:1871-9. 2003
    ..Quantitative analysis of preseroconversion replication rates of HIV is useful for projecting the yield and predictive value of assays targeting primary HIV infection...
  14. ncbi Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand
    Punnee Pitisuttithum
    Department of Clinical Tropical Medicine, Mahidol University, Bangkok 10400, Thailand
    J Infect Dis 194:1661-71. 2006
    ....
  15. ncbi Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1
    A Trkola
    Aaron Diamond AIDS Research Center, New York University School of Medicine, New York 10016, USA
    J Virol 70:1100-8. 1996
    ..consistent with this, antibodies able to block 2G12 binding to recombinant gp120 were not detected in significant quantities in 16 HIV-positive human serum samples...
  16. ncbi The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection
    Nilu Goonetilleke
    Medical Research Council Human Immunology Unit, Weatherall Institute of Molecular Medicine, Oxford University, Oxford OX3 9DS, England, UK
    J Exp Med 206:1253-72. 2009
    ..These included clusters of mutations in envelope that were targeted by NAbs, a few isolated sites that reverted to the consensus sequence, and bystander mutations in linkage with T cell-driven escape...
  17. ncbi Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein
    Anna Le Tortorec
    Department of Infectious Disease, King s College London School of Medicine, Guy s Hospital, London SE1 9RT, United Kingdom
    J Virol 83:11966-78. 2009
    ..Finally, we recapitulated these observations in HIV-2-infected CD4+ T-cell lines, demonstrating that tetherin antagonism and sequestration occur at physiological levels of Env expression during virus replication...
  18. ncbi HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis
    M Juliana McElrath
    Vaccine and Infectious Disease Institute and the HIV Vaccine Trials Network, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Lancet 372:1894-905. 2008
    ..We assessed vaccine-induced immunity and its potential contributions to infection risk...
  19. ncbi Genome-scale RNAi screen for host factors required for HIV replication
    Honglin Zhou
    Department of Virus and Cell Biology, Merck and Co, Inc, West Point, PA 19486, USA
    Cell Host Microbe 4:495-504. 2008
    ..This study highlights both the power and shortcomings of large scale loss-of-function screens in discovering host-pathogen interactions...
  20. ncbi Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1
    Richard E Haaland
    Department of Pathology and Laboratory Medicine, Emory University, Atlanta, Georgia, United States of America
    PLoS Pathog 5:e1000274. 2009
    ....
  21. ncbi Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance
    Chunlin Wang
    Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, CA 94305, USA
    Genome Res 17:1195-201. 2007
    ..With appropriate analysis, ultra-deep pyrosequencing is a promising method for characterizing genetic diversity and detecting minor yet clinically relevant variants in biological samples with complex genetic populations...
  22. ncbi TRBP, a regulator of cellular PKR and HIV-1 virus expression, interacts with Dicer and functions in RNA silencing
    Astrid D Haase
    Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, 4508 Basel, Switzerland
    EMBO Rep 6:961-7. 2005
    ..The TRBP-Dicer interaction shown raises interesting questions about the potential interplay between RNAi and interferon-PKR pathways...
  23. ncbi HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes
    Yukie Iwabu
    Department of Pathology, National Institute of Infectious Diseases, Tokyo 162 8640, Japan
    J Biol Chem 284:35060-72. 2009
    ..Also, we propose the following configuration of BST-2 in tethering virions to the cell surface; each of the dimerized BST-2 molecules acts as a bridge between viral and cell membranes...
  24. ncbi Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy
    Peter W Hunt
    Positive Health Program, San Francisco General Hospital, Bldg 80, Ward 84, 995 Potrero Ave, San Francisco, CA 94110, USA
    J Infect Dis 197:126-33. 2008
    ....
  25. ncbi A quantitative assay for HIV DNA integration in vivo
    S L Butler
    Infectious Disease Laboratory, The Salk Institute for Biological Studies, La Jolla, California, USA
    Nat Med 7:631-4. 2001
    ..The integration assay employs a novel quantitative form of Alu-PCR that should be generally applicable to studies of integrating viruses and gene transfer vectors...
  26. ncbi Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract
    Saurabh Mehandru
    Aaron Diamond AIDS Research Center, The Rockefeller University, 455 First Ave, 7th Fl, New York, NY 10016, USA
    J Exp Med 200:761-70. 2004
    ..Given the importance of the mucosal compartment in HIV-1 pathogenesis, further study to elucidate the significance of the changes observed here is critical...
  27. ncbi Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal trafficking
    Richard S Mitchell
    Department of Medicine, University of California San Diego, La Jolla, CA, USA
    PLoS Pathog 5:e1000450. 2009
    ..Together, the data support a model in which Vpu co-opts the beta-TrCP/SCF E3 ubiquitin ligase complex to induce endosomal trafficking events that remove BST-2 from its site of action as a virion-tethering factor...
  28. ncbi Genomewide association study of an AIDS-nonprogression cohort emphasizes the role played by HLA genes (ANRS Genomewide Association Study 02)
    Sophie Limou
    Conservatoire National des Arts et Metiers, Universite Paris 7, Paris, France
    J Infect Dis 199:419-26. 2009
    ..The present study, the first GWAS of HIV-1 nonprogressors, underscores the potential for some HLA genes to control disease progression soon after infection...
  29. ncbi Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion
    Eri Miyagi
    Laboratory of Molecular Microbiology, Viral Biochemistry Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 0460, USA
    Proc Natl Acad Sci U S A 106:2868-73. 2009
    ....
  30. ncbi Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity
    Patrick Dorr
    Discovery Biology, Pfizer Global Research and Development Sandwich Laboratories, Kent CT13 9NJ, United Kingdom
    Antimicrob Agents Chemother 49:4721-32. 2005
    ..Clinical trials are ongoing to further investigate the potential of using maraviroc for the treatment of HIV-1 infection and AIDS...
  31. ncbi Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo
    Athe M N Tsibris
    Massachusetts General Hospital, Boston, Massachusetts, United States of America
    PLoS ONE 4:e5683. 2009
    ..Greater V3 diversity was observed post-selection. This previously unreported degree of V3 loop sequence diversity has implications for viral pathogenesis, vaccine design, and the optimal use of HIV-1 CCR5 antagonists...
  32. ncbi Molecular architecture of native HIV-1 gp120 trimers
    Jun Liu
    Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Nature 455:109-13. 2008
    ..Our findings elucidate the structure and conformational changes of trimeric HIV-1 gp120 relevant to antibody neutralization and attachment to target cells...
  33. ncbi The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein
    Nanette Van Damme
    The San Diego Department of Veterans Affairs Healthcare System, San Diego, CA 92161, USA
    Cell Host Microbe 3:245-52. 2008
    ....
  34. ncbi Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection
    E S Gray
    AIDS Virus Research Unit, National Institute for Communicable Diseases, Private Bag X4, Sandringham 2131, Johannesburg, South Africa
    J Virol 81:6187-96. 2007
    ..These data provide insights into the kinetics, potency, breadth, and epitope specificity of neutralizing antibody responses in acute HIV-1 subtype C infection...
  35. ncbi HIV-1 integration in the human genome favors active genes and local hotspots
    Astrid R W Schroder
    Infectious Disease Laboratory, The Salk Institute, 10010 North Torrey Pines Road, La Jolla, CA 92037, USA
    Cell 110:521-9. 2002
    ..4 kb region containing 1% of sites. These data document unexpectedly strong biases in integration site selection and suggest how selective targeting promotes aggressive HIV replication...
  36. ncbi Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?
    Leonidas Stamatatos
    1Seattle Biomedical Research Institute, Seattle, Washington, USA
    Nat Med 15:866-70. 2009
    ..A concerted effort of structure-based vaccine design will help guide the development of improved antibody-based vaccines for HIV-1...
  37. ncbi A genome-wide short hairpin RNA screening of jurkat T-cells for human proteins contributing to productive HIV-1 replication
    Man Lung Yeung
    Molecular Virology Section, Laboratory of Molecular Microbiology, NIAID, National Institutes of Health, Bethesda, Maryland 20892 0460, USA
    J Biol Chem 284:19463-73. 2009
    ..We discuss the similarities and differences between our shRNA findings for HIV-1 using a spreading infection assay in human Jurkat T-cells and results from other investigators who used siRNA-based screenings in HeLa or 293T cells...
  38. ncbi Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants
    M R Abrahams
    Institute of Infectious Diseases and Molecular Medicine, Division of Medical Virology, Faculty of Health Sciences, University of Cape Town, Observatory, Cape Town 7925, South Africa
    J Virol 83:3556-67. 2009
    ....
  39. ncbi Decline in the AIDS and death rates in the EuroSIDA study: an observational study
    A Mocroft
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    Lancet 362:22-9. 2003
    ..Since the introduction of highly active antiretroviral therapy (HAART), little is known about whether changes in HIV-1 mortality and morbidity rates have been sustained. We aimed to assess possible changes in these rates across Europe...
  40. ncbi Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial
    Bertran Auvert
    Hopital Ambroise Pare, Assitance Publique Hôpitaux de Paris, Boulogne, France
    PLoS Med 2:e298. 2005
    ..Observational studies suggest that male circumcision may provide protection against HIV-1 infection. A randomized, controlled intervention trial was conducted in a general population of South Africa to test this hypothesis...
  41. ncbi Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8
    Florian Heil
    Institute of Medical Microbiology, Immunology and Hygiene, Technische Universitat Munchen, Trogerstr 9, D 81675 Munich, Germany
    Science 303:1526-9. 2004
    ..These data suggest that ssRNA represents a physiological ligand for TLR7 and TLR8...
  42. ncbi Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission
    Cynthia A Derdeyn
    Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL 35294 USA
    Science 303:2019-22. 2004
    ..This reveals characteristics of the envelope glycoprotein that influence HIV-1 transmission and may have implications for vaccine design...
  43. ncbi HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes
    Kosuke Miyauchi
    Institute of Human Virology and Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Cell 137:433-44. 2009
    ..These findings imply that HIV-1 infects cells via endocytosis and envelope glycoprotein- and dynamin-dependent fusion with intracellular compartments...
  44. ncbi Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update
    Diane E Bennett
    World Health Organization, Geneva, Switzerland
    PLoS ONE 4:e4724. 2009
    ..The updated SDRM list has 93 mutations including 34 NRTI-resistance mutations at 15 RT positions, 19 NNRTI-resistance mutations at 10 RT positions, and 40 PI-resistance mutations at 18 protease positions...
  45. ncbi Setting the stage: host invasion by HIV
    Florian Hladik
    Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Nat Rev Immunol 8:447-57. 2008
    ..Furthermore, we discuss the gaps in our knowledge that are relevant to future studies, which will shape strategies for effective HIV prevention...
  46. ncbi HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation
    Bastien Mangeat
    Department of Dermatology and Venereology, University Hospitals and Medical School of Geneva, University of Geneva, Switzerland
    PLoS Pathog 5:e1000574. 2009
    ..Identification of tetherin binding to Vpu provides a potential novel target for the development of drugs aimed at inhibiting HIV-1 replication...
  47. ncbi Proline-rich (PxxP) motifs in HIV-1 Nef bind to SH3 domains of a subset of Src kinases and are required for the enhanced growth of Nef+ viruses but not for down-regulation of CD4
    K Saksela
    Rockefeller University, New York, NY 10021
    EMBO J 14:484-91. 1995
    ..Thus, CD4 down-regulation and promotion of viral growth are two distinct functions of Nef, and the latter is mediated via SH3 binding...
  48. ncbi The cell biology of HIV-1 virion genesis
    Paul D Bieniasz
    Howard Hughes Medical Institute, Aaron Diamond AIDS Research Center, New York, NY 10016, USA
    Cell Host Microbe 5:550-8. 2009
    ..Here, I review recent progress in these three areas...
  49. ncbi Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy
    Xiping Wei
    Howard Hughes Medical Institute, Department of Medicine, University of Alabama at Birmingham, 35294, USA
    Antimicrob Agents Chemother 46:1896-905. 2002
    ..These findings provide the first evidence for the rapid emergence of clinical resistance to a novel class of HIV-1 entry inhibitors and may be relevant to future treatment strategies involving these agents...
  50. ncbi Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan Africa
    Catherine G Sutcliffe
    Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA
    Lancet Infect Dis 8:477-89. 2008
    ....
  51. ncbi HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites
    Peter D Kwong
    Vaccine Research Center, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nature 420:678-82. 2002
    ..Because this solution is available for cell-surface receptors but not for most antibodies, conformational masking enables HIV-1 to maintain receptor binding and simultaneously to resist neutralization...
  52. ncbi Parallels between cytokinesis and retroviral budding: a role for the ESCRT machinery
    Jez G Carlton
    Department of Infectious Diseases, King s College London School of Medicine, London, UK
    Science 316:1908-12. 2007
    ..Thus, HIV-1 budding and cytokinesis use a similar subset of cellular components to carry out topologically similar membrane fission events...
  53. ncbi The transmembrane domain of BST-2 determines its sensitivity to down-modulation by human immunodeficiency virus type 1 Vpu
    Liwei Rong
    McGill AIDS Centre, Lady Davis Institute Jewish General Hospital, Montreal, Quebec, Canada H3T 1E2
    J Virol 83:7536-46. 2009
    ....
  54. ncbi High-throughput SHAPE analysis reveals structures in HIV-1 genomic RNA strongly conserved across distinct biological states
    Kevin A Wilkinson
    Department of Chemistry, University of North Carolina, Chapel Hill, North Carolina, United States of America
    PLoS Biol 6:e96. 2008
    ..High-throughput SHAPE reveals a comprehensive view of HIV-1 RNA genome structure, and further application of this technology will make possible newly informative analysis of any RNA in a cellular transcriptome...
  55. ncbi Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control
    Stephen A Migueles
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Immunity 29:1009-21. 2008
    ..They also demonstrate that lytic granule contents of memory cells are a critical determinant of cytotoxicity that must be induced for maximal per-cell killing capacity...
  56. ncbi Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection
    Neil M Flynn
    University of California at Davis Medical Center, USA
    J Infect Dis 191:654-65. 2005
    ..10, adjusted for multiple subgroup comparisons). CONCLUSIONS: There was no overall protective effect. The efficacy trends in subgroups may provide clues for the development of effective immunization approaches...
  57. ncbi New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes
    R S Janssen
    Division of HIV AIDS Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    JAMA 280:42-8. 1998
    ..Differentiating individuals with early human immunodeficiency virus 1 (HIV-1) infection from those infected for longer periods is difficult but important for estimating HIV incidence and for purposes of clinical care and prevention...
  58. ncbi Antagonism of CD317 restriction of human immunodeficiency virus type 1 (HIV-1) particle release and depletion of CD317 are separable activities of HIV-1 Vpu
    Christine Goffinet
    Department of Infectious Diseases, Virology, University of Heidelberg, Im Neuenheimer Feld 324, D 69120 Heidelberg, Germany
    J Virol 84:4089-94. 2010
    ..Thus, Vpu can efficiently antagonize virion tethering in the absence of CD317 degradation...
  59. ncbi Inhibiting sexual transmission of HIV-1 infection
    Robin J Shattock
    Department of Cellular and Molecular Medicine, Infectious Diseases, St George s Hospital Medical School, London, UK
    Nat Rev Microbiol 1:25-34. 2003
    ....
  60. ncbi Quantitative detection of increasing HIV type 1 antibodies after seroconversion: a simple assay for detecting recent HIV infection and estimating incidence
    Bharat S Parekh
    Division of AIDS, STD, TB Laboratory Research, and Division of HIV AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    AIDS Res Hum Retroviruses 18:295-307. 2002
    ..This assay should be useful for detecting recent HIV-1 infection and for estimating incidence among diverse HIV-1 subtypes worldwide...
  61. ncbi A cellular restriction dictates the permissivity of nondividing monocytes/macrophages to lentivirus and gammaretrovirus infection
    Rajnish Kaushik
    Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA
    Cell Host Microbe 6:68-80. 2009
    ..Collectively, our results indicate that the relative ability of lentiviruses and gammaretroviruses to transduce nondividing myeloid cells is dependent upon their ability to neutralize a cellular restriction...
  62. ncbi HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype
    Asier Saez Cirion
    Unité de Régulation des Infections Rétrovirales, Institut Pasteur, 75725 Paris, France
    Proc Natl Acad Sci U S A 104:6776-81. 2007
    ..This constitutive antiviral capacity of CD8(+) T cells could account for the control of viral replication in HIC...
  63. ncbi Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures
    Margaret Johnson
    Royal Free Hospital, London, UK
    AIDS 19:685-94. 2005
    ....
  64. ncbi A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load
    J A Arranz Caso
    Infectious Diseases Unit, Hospital Principe de Asturias, Madrid, Spain
    HIV Med 6:353-9. 2005
    ..To assess the antiviral efficacy and safety of switching from a protease inhibitor (PI) to nevirapine in patients with long-term HIV-1 RNA suppression on PI-containing regimens, and to assess its influence in the adherence to treatment...
  65. ncbi No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients
    Jade Ghosn
    Department of Infectious and Tropical Diseases, , Paris, France
    AIDS 19:1643-7. 2005
    ....
  66. ncbi Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial
    Edwin DeJesus
    IDC Research Initiative, Altamonte Springs, FL, USA
    Clin Infect Dis 39:411-8. 2004
    ..Median increase above baseline in CD4(+) cell count was similar (q.d. group, +144 cells/mm(3); b.i.d. group, +146 cells/mm(3)), and the incidences of adverse events, disease progression, and HIV-associated conditions were comparable...
  67. ncbi Human immunodeficiency virus type 1 (HIV-1) genotyping in Rio de Janeiro, Brazil: assessing subtype and drug-resistance associated mutations in HIV-1 infected individuals failing highly active antiretroviral therapy
    J C Couto-Fernandez
    Laboratorio de AIDS e Imunologia Molecular, Departamento de Imunologia, Instituto Oswaldo Cruz FIOCRUZ, 21045 900 Rio de Janeiro, RJ, Brazil
    Mem Inst Oswaldo Cruz 100:73-8. 2005
    ..The maintenance of resistance genotyping programs for HIV-1 failing patients is important to the management of ARV therapies and to attempt and monitor the HIV-1 subtype prevalence in Brazil...
  68. ncbi Efficacy and tolerability of a nucleoside reverse transcriptase inhibitor-sparing combination of lopinavir/ritonavir and efavirenz in HIV-1-infected patients
    Clotilde Allavena
    Service des Maladies Infectieuses et Tropicales/IFR26, , Nantes, France
    J Acquir Immune Defic Syndr 39:300-6. 2005
    ..CONCLUSION: The lopinavir/ritonavir-efavirenz combination is associated with a high rate of virologic response and should be compared with more classic NRTI-containing regimens in randomized and controlled clinical trials...
  69. ncbi Long-term analysis of the resistance development in HIV-1 positive patients treated with protease and reverse transcriptase inhibitors: correlation of the genotype and disease progression
    J Vaclavikova
    Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Flemingovo nam 2, 166 10 Prague, Czech Republic
    Acta Virol 49:29-36. 2005
    ..Efficient yet temporary suppression of viral replication was achieved by a lopinavir (LPV) treatment...
  70. ncbi Discordant response to HAART: reduction of viremia and replicative capacity of HIV strains in patients after genotype guided change of therapy
    L Sarmati
    Department of Public Health, University of Rome Tor Vergata, Rome
    New Microbiol 27:95-8. 2004
    ..1-74.5%). The HIV strains of patients failing HAART showed a progressive impaired replication capacity. In patients failing HAART the impaired replication capacity of HIV strains could justify the persistence of an immune recovery...
  71. ncbi Drug-resistance mutations in antiretroviral-naïve patients with established HIV-1 infection in Mexico
    M Escoto-Delgadillo
    Laboratory of Immunodeficiencies and Human Retrovirus, Western Biomedical Research Center, Mexican Institute of Social Security, Guadalajara, Mexico
    HIV Med 6:403-9. 2005
    ....
  72. ncbi Antiretroviral resistance in individuals presenting therapeutic failure and subtypes of the human immunodeficiency virus type 1 in the Northeast Region of Brazil
    Ana Maria Salustiano Cavalcanti
    Laboratório Central da Secretaria de Saúde, Secretaria de Saúde do Estado de Pernambuco, Recife, PE, 50050 210, Brazil
    Mem Inst Oswaldo Cruz 102:785-92. 2007
    ..The present study showed that there was a high frequency of primary mutations, which offered resistance to nrti and nnrti. Monitoring patients with treatment failure is an important tool for aiding physicians in rescue therapy...
  73. ncbi Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression
    Roy M Gulick
    Weill Medical College of Cornell University, 525 East 68th Street, New York, NY 10021, USA
    AIDS 21:813-23. 2007
    ..To compare a quadruple-nucleoside with an efavirenz-containing regimen for treatment of HIV-1 infection...
  74. ncbi Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children
    H Green
    MRC Clinical Trials Unit, 222 Euston Road, London, NW1 2DA, UK
    AIDS 21:947-55. 2007
    ..To describe the long-term efficacy over 5 years of regimens including combinations of abacavir, lamivudine and/or zidovudine in previously untreated children in the PENTA 5 trial...
  75. ncbi Evolution of resistance mutations during low-level viral replication in HIV-1-infected patients treated with zidovudine/lamivudine/abacavir as a first-line regimen
    Martin Stürmer
    J W Goethe University Hospital, Institute for Medical Virology, Frankfurt, Germany
    Antivir Ther 12:25-30. 2007
    ....
  76. ncbi Virologic response to potent antiretroviral therapy and modeling of HIV dynamics in early pediatric infection
    Paul Palumbo
    Department of Pediatrics, University of Medicine and Dentistry New Jersey Medical School, Newark, NJ, USA
    J Infect Dis 196:23-9. 2007
    ..Similar studies are needed in pediatric populations, in whom differing dynamics might translate into age-specific treatment approaches...
  77. ncbi Antiretroviral resistance
    Anna Maria Geretti
    J HIV Ther 11:72-3. 2006
  78. ncbi High frequency of drug resistance mutations in human immunodeficiency virus type 1-infected Korean patients treated with HAART
    Heungsup Sung
    Department of Microbiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
    AIDS Res Hum Retroviruses 23:1223-9. 2007
    ..As the first report on resistance mutations to HAART in Korea, our data suggest that genotyping-guided treatment as well as education for compliance are required for better care...
  79. ncbi Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies
    R Scott Braithwaite
    Section of General Internal Medicine, Department of Medicine, Yale University, 950 Campbell Avenue, West Haven, CT 06516, USA
    AIDS 21:1579-89. 2007
    ..We aimed to determine adherence, virological, and immunological outcomes one year after starting a first combination antiretroviral therapy (ART) regimen...
  80. ncbi Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection
    Patrick F Smith
    Hoffman La Roche Inc, Clinical Pharmacology, Nutley, NJ 07110 1199, USA
    Antimicrob Agents Chemother 51:3574-81. 2007
    ..45 log(10), with individual patients having reductions of greater than 0.7 log(10). No bevirimat resistance mutations were detected during the course of the study...
  81. ncbi Rare selection of the K65R mutation in antiretroviral-naive patients failing a first-line abacavir/ lamivudine-containing HAART regimen
    Diane Descamps
    Laboratoire de Virologie, Hopital Bichat Claude Bernard, Paris, France
    Antivir Ther 11:701-5. 2006
    ..This study examined whether, in the context of a first-line abacavir/lamivudine highly active antiretroviral therapy (HAART) regimen, K65R might occur as a minority population where L74V was detected at virological failure...
  82. ncbi Dynamics of HIV viral load in blood and semen of patients under HAART: impact of therapy in assisted reproduction procedures
    Giovanni Battista La Sala
    Division of Obstetrics, Gynecology and Reproduction Medicine, ASMN Reggio Emilia, Italy
    AIDS 21:377-9. 2007
    ..001). These findings emphasize the negative role of HAART, but not of HIV-1 infection, in determining semen alterations...
  83. ncbi Efficacy and safety of tenofovir double-dose in treatment-experienced HIV-infected patients: the TENOPLUS study
    Stephanie Dominguez
    Département des Maladies Infectieuses et Tropicales INSERM U720, CHU Pitie Salpetriere, Paris, France
    J Med Virol 79:105-10. 2007
    ..This add-on pilot study supports the concept of double dose tenofovir to virologically overcome the decreased sensitivity of NRTI-resistant viruses. However, the safety of this regimen needs to be considered carefully...
  84. ncbi Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES)
    S H Lowe
    International Antiviral Therapy Evaluation Center IATEC, University of Amsterdam, Amsterdam, The Netherlands
    HIV Clin Trials 6:235-45. 2005
    ..To improve the dosing frequency and pill burden of antiretroviral therapy, we compared two once-daily dosed regimens to a twice-daily dosed regimen...
  85. ncbi Effect of first line therapy including efavirenz and two nucleoside reverse transcriptase inhibitors in HIV-infected children
    Markus B Funk
    Children s Hospital, Johann Wolfgang Goethe University, Frankfurt, Germany
    Eur J Med Res 10:503-8. 2005
    ..In an intent-to-treat study, reduction of viral load, increase in CD4 cell count, clinical benefit and adverse reactions were examined in HIV-infected children receiving first line therapy including efavirenz...
  86. ncbi Factors associated with sustained virologic suppression in patients receiving antiretroviral therapy in an urban HIV care clinic
    Tania Purkayastha
    Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, AIDS Center Schiff 1, 111 East 210th Street, Bronx, NY 10467, USA
    AIDS Patient Care STDS 19:785-93. 2005
    ..Computerized query of the hospital information system proved to be a powerful tool for the identification of study patients in a real-world clinic environment...
  87. ncbi HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time
    Jade Ghosn
    Laboratoire de Virologie, CHU Necker Enfants Malades, Université René Descartes Paris, France
    AIDS 20:159-70. 2006
    ....
  88. ncbi Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness
    David R Bangsberg
    Epidemiology and Prevention Interventions Center, Division of Infectious Diseases, San Francisco General Hospital, UCSF, San Francisco, California 94143 1372, USA
    AIDS 20:223-31. 2006
    ....
  89. ncbi Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study)
    Antonella Castagna
    Clinic of Infectious Diseases, Vita Salute San Raffaele University, Milan, Italy
    AIDS 20:795-803. 2006
    ..We compared the immunological and clinical outcomes of lamivudine monotherapy and complete therapy interruption in the treatment of HIV-1-infected patients harbouring lamivudine-resistant virus...
  90. ncbi [Resistance to anti-retroviral therapy in Chilean patients with HIV-1 from 2002 to 2005]
    Alejandro Afani S
    Seccion de Inmunologia, Departamento de Medicina, Hospital Clinico, Universidad de Chile, Santiago, Chile
    Rev Med Chil 135:1237-44. 2007
    ..Resistance limits the effectiveness of anti-retroviral therapy. In Chile, there is free access to highly active anti-retroviral therapy since 2001, but there is no information about the frequency of mutations associated to drug resistance...
  91. ncbi Net benefits of resistance testing directed therapy compared with standard of care in HIV-infected patients with virological failure: A meta-analysis
    Javier Ena
    HIV Unit, Department of Internal Medicine, Hospital Marina Baixa, Avda Alcalde En Jaime Botella Mayor 7, 03570 Villajoyosa, Alicante, Spain
    Enferm Infecc Microbiol Clin 24:232-7. 2006
    ..We incorporated the latest available information to evaluate the net benefit of using resistance testing in HIV-infected patients with virological failure...
  92. ncbi Viral replication under combination antiretroviral therapy: a comparison of four different regimens
    Azra C Ghani
    Department of Infectious Disease Epidemiology, Faculty of Medicine, Imperial College of Science, Technology and Medicine, London, UK
    J Acquir Immune Defic Syndr 30:167-76. 2002
    ..04; 95% CI, 1.0-1.07). Measurement of viral load after approximately 7 days provided the most accurate measure of the degree of viral suppression induced by a given drug regimen...
  93. ncbi Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination with efavirenz: results of a systematic overview
    John A Bartlett
    Duke University Medical Center, Durham, North Carolina 27710, USA
    HIV Clin Trials 8:221-6. 2007
    ..However, the nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) components may also affect efficacy...
  94. ncbi MIV-310 reduces HIV viral load in patients failing multiple antiretroviral therapy: results from a 4-week phase II study
    Christine Katlama
    Département des Maladies Infectieuses et Tropicales INSERM E0214, Hopital Pitie Salpetriere, Paris, France
    AIDS 18:1299-304. 2004
    ..MIV-310 (alovudine), a nucleoside reverse transcriptase inhibitor, potently inhibits the replication of highly mutated strains of HIV in vitro. We examined the efficacy of MIV-310 in highly pretreated patients...
  95. ncbi The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study
    Christian Laurent
    , France
    AIDS 16:1363-70. 2002
    ..Contrary to other recent studies in Africa, viral resistance rarely emerged...
  96. ncbi The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to < 400 copies/ml
    Philippa J Easterbrook
    Department of HIV/GUM, Guy's, King's and St Thomas' School of Medicine, King's College Hospital, London, UK
    AIDS 16:1521-7. 2002
    ..This supports the adoption of a more pro-active approach to treatment intensification and the need for caution with structured treatment interruptions...
  97. ncbi Successful simplification of HAART in patients with acute primary HIV infection
    A Sinicco
    Department of Infectious Diseases, University of Turin, Italy
    J Biol Regul Homeost Agents 16:69-72. 2002
    ....
  98. ncbi Improved long-term suppression of HIV-1 replication with a triple-class multidrug regimen compared with standard of care antiretroviral therapy
    Rieneke M E van Praag
    National AIDS Therapy Evaluation Center (NATEC, Department of Internal Medicine, Division of Infectious Diseases, Tropical Medicine and AIDS, University of Amsterdam, The Netherlands
    AIDS 16:719-25. 2002
    ..CONCLUSION: This proof-of-principle study demonstrates that the use of an alternative multidrug regimen results in stronger long-term suppression of pVL compared with clinically successful treatment with standard therapy...
  99. ncbi Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy
    Soo Aleman
    Division of Clinical Virology, Karolinska Institutet, Huddinge University Hospital, S-141 86 Stockholm, Sweden
    AIDS 16:1039-44. 2002
    ..This serial accumulation of mutations is likely to exhaust future drug options..
  100. ncbi Changes in plasma HIV-1-RNA viral load and CD4 cell counts, and lack of zidovudine resistance among pregnant women receiving short-course zidovudine
    René Anatole Ekpini
    Projet RETRO CI, BP 1712, 01 Abidjan, Cote d Ivoire
    AIDS 16:625-30. 2002
    ..To describe changes in HIV-1 plasma viral load (VL) and CD4 cell counts and to assess zidovudine resistance associated with a short course of oral zidovudine during late pregnancy...
  101. ncbi A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy
    Calvin J Cohen
    Community Research Initiative of New England, Boston, MA 02215, USA
    AIDS 16:579-88. 2002
    ..003). CONCLUSION: Antiretroviral treatment guided prospectively by PRT led to the increased use of "active" antiretroviral agents and was associated with a significantly better virological response...

Research Grants81

  1. Tat Transactivation
    BORIS MATIJA PETERLIN; Fiscal Year: 2010
    ..These studies will reveal the complex RNA-protein world of P-TEFb and how HIV subverts these cellular complexes for its replication in cells. ..
  2. Tat Transactivation
    B Matija Peterlin; Fiscal Year: 2007
    ..These studies will reveal the complex RNA-protein world of P-TEFb and how HIV subverts these cellular complexes for its replication in cells. ..
  3. Establishment fo HIV infection in cotton rats
    Jorge Blanco; Fiscal Year: 2007
    ....
  4. TRANSCRIPTION ACTIVATION BY HIV, TAT, HTLV TAX & HBV PX
    Michael Green; Fiscal Year: 2004
    ..However, BEF works by a different mechanism, as a molecular chaperone. Experiments are proposed to further study the mechanism of BEF action. ..
  5. Structure and Function of Ribonucleoprotein Complexes Modulating HIV Replication
    Tariq M Rana; Fiscal Year: 2010
    ..These results would also be valuable in developing new strategies for blocking the expression of retroviral or other disease- related genes. ..
  6. Cytidine deaminase and HIV-1 replication
    Hui Zhang; Fiscal Year: 2007
    ..We believe that these alternative but complementary approaches would enrich our knowledge regarding this anti-viral defense system. The research result from these projects will lead to find a novel strategy to combat HIV-1 replication. ..
  7. Targeting Viral Envelope Glycoproteins with Synthetic Antibodies
    Jonathan Lai; Fiscal Year: 2010
    ..We are using this new technology to identify novel antibodies against viral targets. This work will provide new tools to understand viral infection and how this process can be inhibited by therapeutic agents or vaccines. ..
  8. Methamphetamine, HIV, Neuroinflammation and Behavior
    Rodney Johnson; Fiscal Year: 2007
    ..Therefore, the goal of this proposal is to investigate if MA use and HIV-1 infection unite to exacerbate the cognitive and motor complications associated with HIV disease and produce a heightened neuroinflammatory state. ..
  9. The Enzymology of M-MuLV and HIV Replication
    JAMES CHAMPOUX; Fiscal Year: 2007
    ..The analysis of reverse transcriptase fidelity during displacement synthesis will directly contribute to our understanding of how the virus rapidly evolves during progression to AIDS. ..
  10. The Enzymology of M-MuLV and HIV Replication
    JAMES CHAMPOUX; Fiscal Year: 2009
    ..The analysis of reverse transcriptase fidelity during displacement synthesis will directly contribute to our understanding of how the virus rapidly evolves during progression to AIDS. ..
  11. High Specificity HIV-1 Markers Predictive of Neuro-AIDS
    Brian Wigdahl; Fiscal Year: 2010
    ....
  12. Single and multi-component biguanide-based microbicides
    Mohamed Labib; Fiscal Year: 2007
    ....
  13. HIV vectors for stem cell and intrakine gene delivery
    Richard Sutton; Fiscal Year: 2004
    ..These intervector comparisons should serve to identify the superior transgene combination. If successful, these studies may facilitate the development of clinical-grade anti-HIV lentiviral vectors for transduction of HSC. ..
  14. MOLECULAR RECOGNITION OF HIV1 PRIMER TRNA LYS
    Karin Musier Forsyth; Fiscal Year: 2001
    ..c) Stopped-flow fluorescence techniques will be used to investigate the kinetic mechanism of NC unwinding and annealing of tRNALys,3. ..
  15. 3D Structure of HIV-1 psi-Site
    Daniele Fabris; Fiscal Year: 2005
    ..abstract_text> ..
  16. MOLECULAR MECHANISM OF TAT INDUCED ANGIOGENESIS
    Cindy Morris; Fiscal Year: 2002
    ....
  17. HIV-1 chemoprophylaxis and archived drug resistance in infants
    Deborah Persaud; Fiscal Year: 2007
    ....